<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03749408</url>
  </required_header>
  <id_info>
    <org_study_id>CEBD-CU-2012-12-24</org_study_id>
    <nct_id>NCT03749408</nct_id>
  </id_info>
  <brief_title>Effect of Addition of Mannitol to Bupivacaine on IANB Success and Post-endodontic Pain</brief_title>
  <official_title>Effect of Addition of 0.5 Mol/L Mannitol to 0.5% Bupivacaine on IANB Success and Post-endodontic Pain in Mandibular Molars With Irreversible Pulpitis: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inferior alveolar nerve block using either 0.5% bupivacaine alone or in addittion to mannitol
      in patients with irreversible pulpitis in mandibular molars.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with irreversible pulpitis in mandibular molars will be selected according to the
      eligibility criteria and patients are then randomized to either using 0.5% bupivacaine alone
      or in addition to mannitol. Anesthetic success and postoperative pain will then be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain intensity ranging from 0-10 where 0 means no pain, 10 the worst pain</measure>
    <time_frame>6 hours</time_frame>
    <description>using pain scale ranging from 0-10 where 0 means no pain, 10 the worst pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain intensity ranging from 0-10 where 0 means no pain, 10 the worst pain</measure>
    <time_frame>12 hours</time_frame>
    <description>using pain scale ranging from 0-10 where 0 means no pain, 10 the worst pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain intensity ranging from 0-10 where 0 means no pain, 10 the worst pain</measure>
    <time_frame>24 hours</time_frame>
    <description>using pain scale ranging from 0-10 where 0 means no pain, 10 the worst pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain intensity ranging from 0-10 where 0 means no pain, 10 the worst pain</measure>
    <time_frame>48 hours</time_frame>
    <description>using pain scale ranging from 0-10 where 0 means no pain, 10 the worst pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain intensity ranging from 0-10 where 0 means no pain, 10 the worst pain</measure>
    <time_frame>72 hours</time_frame>
    <description>using pain scale ranging from 0-10 where 0 means no pain, 10 the worst pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anesthetic success</measure>
    <time_frame>1 hour</time_frame>
    <description>yes or no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lip numbness duration</measure>
    <time_frame>24 hours</time_frame>
    <description>recorded in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication intake</measure>
    <time_frame>72 hours</time_frame>
    <description>yes or no</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Irreversible Pulpitis</condition>
  <arm_group>
    <arm_group_label>bupivacaine plus mannitol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5% bupivacaine with 1:200,000 epinephrine plus 1.5 ml of 0.5 mol/L mannitol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bupivacaine alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5% bupivacaine with 1:200,000epinephrine alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine plus mannitol</intervention_name>
    <description>local anesthesia</description>
    <arm_group_label>bupivacaine plus mannitol</arm_group_label>
    <other_name>vivacaine plus mannitol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine alone</intervention_name>
    <description>local anesthesia</description>
    <arm_group_label>bupivacaine alone</arm_group_label>
    <other_name>vivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients; age between 17-35 years old.

          2. Males or Females.

          3. Medically-free patients

          4. Patients suffering from symptomatic irreversible pulpitis without apical periodontitis
             in mandibular molar teeth.

          5. Positive patients' acceptance for participation in the study.

        Exclusion Criteria:

          -  Patients who had any analgesic during proceeding 12 hours before the treatment.

          -  Teeth with necrotic, infected pulp, swelling or symptomatic apical periodontitis
             (apical abscess).

          -  Pregnant females.

          -  Patients with history of significant medical conditions (contraindication of mannitol
             use).

          -  Addiction

          -  Psycological disturbance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 15, 2018</study_first_submitted>
  <study_first_submitted_qc>November 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2018</study_first_posted>
  <last_update_submitted>November 20, 2018</last_update_submitted>
  <last_update_submitted_qc>November 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Safeya AbdelRahaman Hassan</investigator_full_name>
    <investigator_title>assistant lecturer</investigator_title>
  </responsible_party>
  <keyword>inferior alveolar nerve block</keyword>
  <keyword>long-acting local anesthesia</keyword>
  <keyword>bupivacaine</keyword>
  <keyword>mannitol</keyword>
  <keyword>symptomatic irreversible pulpitits</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulpitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

